Visit Contract Pharma
at Booth #1921

MilliporeSigma Launches BioContinuum Platform


Aims to improve efficiency, simplify plant operations and provide greater quality and consistency of bio manufacturing

MilliporeSigma has launched its new BioContinuum Platform aimed at advancing biotherapeutic drug manufacturing with improved efficiency, simplified plant operations and greater quality and consistency. The company introduced this expanded offering at PharmSci360 conference in Washington, D.C.
“MilliporeSigma’s new, adaptive platform of products, applications and expertise will allow customers to bring new therapies to patients in need, faster and more cost-effectively than ever before,” said Udit Batra, chief executive officer, MilliporeSigma. “Our unique and holistic approach to next-generation bioprocessing allows us to realize the benefits of process intensification throughout the entire process, not gained by focusing on one area at a time.”
Continuous bioprocessing involves integration of batch-based, separate manufacturing steps into a connected process, enabling continuous flow from the addition of raw materials through product harvest, purification and testing. Pilot studies suggest that conversion to such a manufacturing method may reduce manufacturing costs by as much as 50 percent. 
“We are advancing this industry by improving process economics without sacrificing titer or product quality while minimizing waste, energy consumption and raw material use,” Batra added.
The products, documentation and MilliporeSigma’s knowledge base for application and technical support included with the BioContinuum Platform, aims to help to simplify customers’ processes, save time and prevent risk. 
MilliporeSigma also introduced its expanded Pellicon Single-Pass Tangential Flow Filtration product, which adds to the purification portfolio of the BioContinuum Platform. According to the company, the application offers intensified purification for more productive, high capacity and cost-effective downstream processes for higher titer and connected or continuous processes.